Showing 5681-5690 of 7540 results for "".
- The Dermatology Practice of the Future: AI-Powered Piction Health Dermatology Launches in Massachusettshttps://practicaldermatology.com/news/the-dermatology-practice-of-the-future-ai-powered-piction-health-dermatology-launches-in-mass/2461923/Piction Health Dermatology, an AI-enabled dermatology virtual clinic, is now open for Massachusetts residents. Piction's virtual clinic merges artificial intelligence (AI) with the expertise of board-certified dermatologists. Patients complete a short medical in
- UF Researcher Recognized for Life’s Work on Neurofibromatosishttps://practicaldermatology.com/news/uf-researcher-recognized-for-lifes-work-on-neurofibromatosis/2461922/Margaret “Peggy” Wallace, PhD, a professor in the department of molecular genetics and microbiology in the University of Florida College of Medicine, has received an award from the Children’s Tumor Foundation in recognition of her significant contributions to neurofibromatosis r
- Study: Natural Gas Odorants Linked to Skin Rasheshttps://practicaldermatology.com/news/study-natural-gas-odorants-linked-to-skin-rashes/2461918/Odorants are widely used in natural gas for leak detection and may induce a range of adverse health symptoms at very low concentrations including skin rashes, according to a new study in Current Environm
- PSA: Vets Warn That Minoxidil May Be Deadly to Petshttps://practicaldermatology.com/news/vets-warn-that-minoxidil-may-be-deadly-to-pets/2461917/Products like Rogaine, which contain minoxidil, can be very dangerous to animals, warn toxicology experts at Pet Poison Helpline. “Cats are particularly sensitive to this medication, and any exposure can result in severe poisoning and potentially death,” says Renee
- Positive Topline Data Seen in Phase II Trial of LNK01001 in ADhttps://practicaldermatology.com/news/positive-topline-data-seen-in-phase-ii-trial-of-lnk01001-in-ad/2461916/Lynk Pharmaceuticals Co., Ltd.’s LNK01001 performed well in a Phase II clinical trial for the treatment of atopic dermatitis (AD), according to positive topline data from the Company. LNK01001 is a highly selective JAK1 inhibitor that blocks JAK1 without crossing over onto ot
- August Is Psoriasis Action Month: Experts Offer Treatment Tipshttps://practicaldermatology.com/news/august-is-psoriasis-action-month-experts-offer-treatment-tips/2461915/August is Psoriasis Action Month and serves as a good time to make sure that your patients are being adequately treated with available therapies, psoriasis experts tell DermWire. Psoriasis is common, affecting 7.5 million in the US, one-third of whom are candidates for either
- Evolus Rolls Out New Branding for Jeuveauhttps://practicaldermatology.com/news/evolus-rolls-out-new-branding-for-jeuveau/2461913/Evolus, Inc. is unveiling its new branding for Jeuveau (prabotulinumtoxinA-xvfs). The new Jeuveau imagery reflects today’s consumers, many of whom are millennials and younger. The “Jeuveau, You See Me” marketing campaign uses inclusive messaging to encourage
- Revealed: Why Tans Appear After Leaving the Beachhttps://practicaldermatology.com/news/revealed-why-tans-appear-after-leaving-the-beach/2461906/New research uncovers the science behind why the body's tanning process does not occur immediately after sun exposure, but only after a few hours or even days. The mechanism that repairs our DNA takes precedence over all other systems in the cell, temporarily inhibiting the pi
- RoC Skincare Expands The Look Forward Project to Instill Optimism Among the Next Generationhttps://practicaldermatology.com/news/roc-skincare-expands-the-look-forward-project-to-instill-optimism-among-the-next-generation/2461905/RoC Skincare is expanding The RoC Look Forward Project in partnership with Sarah Jessica Parker. The initiative was first launched in 2022 to celebrate the power of optimism and its positive impact on long-term health and wellbeing. Now, the Look Forward
- Abeona Therapeutics Submits Briefing Package for Pre-BLA Meeting with FDA in August 2023https://practicaldermatology.com/news/abeona-therapeutics-submits-briefing-package-for-pre-bla-meeting-with-fda-in-august-2023/2461901/Abeona Therapeutics Inc. completed the submission of the briefing package to the U.S. Food and Drug Administration (FDA) for the Company’s pre-Biologics License Application (BLA) meeting in August 2023. The purpose of the meeting is to discuss the format, content, and accept